Is big bad or bearable? Long-term renal transplant outcomes in obese recipients

被引:4
|
作者
McCloskey, O. M. [1 ]
Devine, P. A. [1 ]
Courtney, A. E. [1 ]
McCaughan, J. A. [1 ]
机构
[1] Belfast City Hosp, Reg Nephrol & Transplant Unit, Belfast BT9 7AB, Antrim, North Ireland
关键词
BODY-MASS INDEX; KIDNEY-TRANSPLANTATION; RISK-FACTOR; MORTALITY; DISEASE; MANAGEMENT; SURVIVAL; DIALYSIS; IMPACT; DEATH;
D O I
10.1093/qjmed/hcx258
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The global obesity epidemic has implications for kidney transplantation. There are conflicting reports regarding the impact of obesity on long-term post-transplant outcomes. Aim: To explore the impact of body mass index (BMI) on long-term outcomes after kidney transplantation. Design: The association between BMI and cardiovascular disease, cancer, post-transplant diabetes mellitus, graft and recipient survival was investigated in recipients who had been transplanted at least ten years previously. Methods: All consecutive adult renal transplant recipients who received first, deceased donor, transplants between 1986 and 2005 in Northern Ireland were followed-up until 2016. Results: A total of 328 patients were eligible. Of them, 96 were overweight with a BMI 25.0-29.9 kg/m(2), and 56 were obese with a BMI exceeding 29.9 kg/m2. Median follow-up time was 16.7 years. In multivariate analysis recipient BMI was associated with the development of post-transplant diabetes mellitus (P = 0.003), but not with new cardiovascular disease (P = 0.78). Cancer was less common in recipients with a higher BMI (hazard ratio (HR) 0.58, P< 0.001). BMI at the time of transplantation did not significantly influence graft (P = 0.28) or recipient survival (P = 0.13). Conclusions: Increased BMI at time of transplantation is associated with an increased risk of post-transplant diabetesmellitus but not new cardiovascular disease ormalignancy. Long-termgraft and recipient survival is not impacted. Potential recipients should not be excluded fromtransplantation solely on the basis of obesity, rather it should be considered as one part of an individualized risk stratification, based on comorbidity and considering the risk of death onmaintenance dialysis.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 50 条
  • [41] COSTS OF LONG-TERM POST-TRANSPLANT CARE IN RENAL TRANSPLANT RECIPIENTS
    Labus, Anna
    Niemczyk, Mariusz
    Czyzewski, LUkasz
    Fliszkiewicz, Magda
    Kulesza, Andrzej
    Mucha, Krzysztof
    Paczek, Leszek
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [42] SURGICAL COMPLICATIONS AND OUTCOMES IN OBESE RENAL TRANSPLANT RECIPIENTS
    Yeung, Emily
    Cheung, Dennison
    Kitching, A. Richard
    Gingold, Michael
    Ryan, Jessica
    NEPHROLOGY, 2022, 27 : 21 - 21
  • [43] Long-term tacrolimus versus long-term ciclosporin in renal transplant recipients with poor graft function
    Pattison, James
    Sacks, Steven
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2008, 4 (11): : 598 - 599
  • [44] Long-term tacrolimus versus long-term ciclosporin in renal transplant recipients with poor graft function
    James Pattison
    Steven Sacks
    Nature Clinical Practice Nephrology, 2008, 4 : 598 - 599
  • [45] The impact of hyperlipidemia on the long-term outcome of renal transplant recipients.
    Tanabe, K
    Tokumoto, T
    Harano, M
    Inui, M
    Suzuki, K
    Ishikawa, N
    Yagisawa, T
    Shimizu, T
    Shinmura, H
    Nakajima, I
    Tojinbara, T
    Fuchinoue, S
    Agishi, T
    Toma, H
    TRANSPLANTATION, 1999, 67 (07) : S170 - S170
  • [46] Endogenous erythropoietin levels and anemia in long-term renal transplant recipients
    Zadrazil, Josef
    Horak, Pavel
    Horcicka, Vladko
    Zahalkova, Jana
    Strebl, Pavel
    Hruby, Miroslav
    KIDNEY & BLOOD PRESSURE RESEARCH, 2007, 30 (02): : 108 - 116
  • [47] Risk factors for hyperlipidemia in long-term pediatric renal transplant recipients
    Silverstein, DM
    Palmer, J
    Polinsky, MS
    Braas, C
    Conley, SB
    Baluarte, HJ
    PEDIATRIC NEPHROLOGY, 2000, 14 (02) : 105 - 110
  • [48] Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients
    Kirchner, GI
    Mueller, L
    Winkler, M
    Loss, M
    Roechte, F
    Deters, M
    Christians, U
    Kaever, V
    Klempnauer, J
    Sewing, KF
    Manns, MP
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (06) : 2233 - 2234
  • [49] Risk factors for hyperlipidemia in long-term pediatric renal transplant recipients
    D. M. Silverstein
    J. Palmer
    M. S. Polinsky
    C. Braas
    S. B. Conley
    H. J. Baluarte
    Pediatric Nephrology, 2000, 14 : 105 - 110
  • [50] The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy
    Ondruš D.
    Pribylincová V.
    Breza J.
    Bujdák P.
    Mikloši M.
    Řezníček J.
    Zvara V.
    International Urology and Nephrology, 1999, 31 (4) : 417 - 422